# PTM-101

Source: https://onco.cc/drugs/ptm-101/  
OnCo record `ptm-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTM-101 is an experimental absorbable implant releasing paclitaxel, a taxane chemotherapy, locally from PanTher Therapeutics, in phase 1 trials for pancreatic ductal adenocarcinoma.

## Summary

PTM-101 is an absorbable implant releasing paclitaxel, a taxane chemotherapy, locally from PanTher Therapeutics. An absorbable product containing paclitaxel, placed at the tumour by a routine laparoscopic procedure, giving continuous high-dose chemotherapy at the tumour site. Its furthest stage is phase 1, for pancreatic ductal adenocarcinoma (borderline resectable and locally advanced). ClinicalTrials.gov registers it in one study linked below. Phase 1b NCT06673017 recruiting, as an addition to neoadjuvant therapy in borderline resectable and locally advanced pancreatic cancer. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: PTM-101
- Modality: Absorbable implant releasing paclitaxel, a taxane chemotherapy, locally
- Mechanism: An absorbable product containing paclitaxel, placed at the tumour by a routine laparoscopic procedure, giving continuous high-dose chemotherapy at the tumour site.

## Sources

- PanTher Therapeutics: panthertx.com: https://panthertx.com/pipeline
- PanTher Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06673017
- ClinicalTrials.gov: trials of PTM-101: https://clinicaltrials.gov/search?intr=PTM-101

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [PanTher Therapeutics](https://onco.cc/companies/panther-therapeutics/)
- trials: [PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct06673017/)

---
JSON: https://onco.cc/api/v1/entities/ptm-101.json